Salvage Therapy of Multiple Myeloma: The New Generation Drugs

Table 3

New generation drugs in monotherapy or combined to novel agents.

Drug	Association to novel agents	Phase	Dosage	𝑁	ORR	Reference
Carfilzomib	Monotherapy	2	20–27 mg/m^2	257	36	[13]
Carfilzomib	In combination with lenalidomide and dexamethasone	1/2	27 mg/m^2	51	78	[14]
Carfilzomib	In combination with pomalidomide	1/2	27 mg/m^2	82	70	[15]
Ixazomib	Monotherapy	1/2	2.97 mg/m^2	32	26	[16]
Pomalidomide	Monotherapy	1/2	4 mg	38	42	[17]
Pomalidomide	In combination with high dose dexamethasone	3	4 mg	455	31	[18]
Pomalidomide	In combination with cyclophosphamide and prednisone	1/2	2.5 mg	69	50	[19]
Perifosine	In combination with bortezomib	1/2	50 mg	84	41	[20]
Perifosine	In combination with lenalidomide	1	50–100 mg	32	73	[21]
Vorinostat	In combination with bortezomib	3	400 mg	637	56.2	[22]
Panobinostat	In combination with bortezomib	1b	20 mg	47	52.9	[23]
Panobinostat	In combination with bortezomib and dexamethasone	2	20 mg	55	34.5	[24]